Evidence map›Paper›PMID 33479589›Full record

ArticleDiabetology international2021

Improved insulin sensitivity with sodium-glucose cotransporter 2 inhibitor treatment in a patient with slowly progressive type 1 diabetes mellitus with metabolic syndrome: a case report.

Toshiharu Ishizuka, Yoshiharu Tokuyama, Atsuya Horie, Azuma Kanatsuka

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Toshiharu IshizukaCredo Sato Clinic, 2138-1, Wakamatsu-cho, Wakaba-ku, Chiba, 264-0021 Japan.ORCID 0000-0002-0564-2534
Yoshiharu TokuyamaKashiwado Hospital, 2-21-8, Nagasu, Chuo-ku, Chiba, 260-0854 Japan.
Atsuya HorieDiabetes Center, Chiba Central Medical Center, 1835-1, Kasori-cho, Wakaba-ku, Chiba, 264-0017 Japan.
Azuma KanatsukaDiabetes Center, Chiba Central Medical Center, 1835-1, Kasori-cho, Wakaba-ku, Chiba, 264-0017 Japan.
Teikyo University Chiba Medical Center · JPChiba Hospital · JPSatou Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report the clinical course of a 56-year-old Japanese patient with slowly progressive type 1 diabetes mellitus, metabolic syndrome, non-alcoholic fatty liver disease, and severe insulin resistance. The patient's intravenous glucose tolerance test indicated marked reductions in insulin sensitivity and endogenous insulin secretion. Accordingly, administration of ipragliflozin l-proline, a sodium-glucose cotransporter 2 inhibitor, promoted improvements in insulin sensitivity and blood glucose levels, as well as a decrease in visceral fat, improvement in dyslipidemia, and decrease in hepatic lipid content, suggesting the potential efficacy of sodium-glucose cotransporter 2 inhibitors for obese patients with type 1 diabetes mellitus exhibiting insulin resistance.

Indexed as

Insulin resistanceMetabolic syndromeNon-alcoholic fatty liver diseaseSlowly progressive type 1 diabetes mellitusSodium-glucose cotransporter 2 inhibitor

Identifiers

PMID33479589
PMCPMC7790962
OpenAlexW3035126802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.